GLP1R and obesity disorder: These findings were unexpected as the 5-HT2C receptor agonist lorcaserin was a previously used treatment for obesity prior to being recalled from increasing the risk of cancer development and as the appetite-suppressing effects of acute peripheral GLP-1 are diminished in 5-HT2C receptor KO mice [110, 111].